In addition, in a retrospective cohort of NSCLC patients with PD-L1 expression ≥ 50% treated with first-line pembrolizumab, obese patients had higher response rates and longer progression free survival (PFS) and OS compared to normal weight patients8. The gene discussed is CD274; the disease is non-small cell lung carcinoma.